Aduro Biotech to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 03 2019 - 8:00AM
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T.
Isaacs, chairman, president and chief executive officer of Aduro,
is scheduled to present at the 37th Annual J.P. Morgan Healthcare
Conference in San Francisco, California on Thursday, January 10,
2019 at 11:30 am PST.
To access the live webcast and subsequent archived recording of
this and other company presentations, please visit the investor
section of Aduro's website at www.aduro.com. The archived webcast
will remain available for replay on Aduro’s website for 30
days.
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that are intended to transform the
treatment of challenging diseases. Aduro's technologies, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications, autoimmune diseases and have
the potential to expand into infectious diseases. Aduro's STING
pathway activator technology is designed to activate the STING
receptor in immune cells, which may result in a potent
tumor-specific immune response. ADU-S100 (MIW815) is the first
STING pathway activator compound to enter the clinic and is
currently being evaluated in a Phase 1 clinical trial as a single
agent and in combination with ipilimumab and in a Phase 1b
combination trial with spartalizumab (PDR001), an investigational
anti-PD-1 monoclonal antibody. Aduro's B-select monoclonal antibody
technology, including BION-1301, an anti-APRIL antibody, is
comprised of a number of immune modulating assets in research and
development. Aduro is collaborating with leading global
pharmaceutical companies to expand its products and technologies.
For more information, please visit www.aduro.com.
|
|
Investor
Relations Contact: |
Media
Contact: |
Noopur
Liffick |
Aljanae
Reynolds |
510-809-2465 |
510-809-2452 |
investors@aduro.com |
press@aduro.com |
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2023 to Apr 2024